News Releases Home Synthetic Biology The History of Synthetic Biology Living Medicines Designing Synthetic Biotic™ Medicines Pipeline + Programs For Patients Our People Leadership Board of Directors Founders and Advisors Join Us Investors + Media Company Overview News & Events News Releases Event Calendar Presentations & Publications Stock Information Corporate Governance Financials Investor Resources Items Per Page 102550 Year None201920182017201620152014 June 25, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018 June 25, 2018 Synlogic Joins Russell 3000® Index June 11, 2018 Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria June 4, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® May 15, 2018 Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update May 10, 2018 Synlogic Announces Leadership Change April 25, 2018 Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria April 18, 2018 Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria April 16, 2018 Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting April 6, 2018 Synlogic Announces Registered Direct Offering of Common Stock Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 31 - 40 of 83 Email Alerts Contact IR RSS Feeds Print Page Email Page
Items Per Page 102550 Year None201920182017201620152014 June 25, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018 June 25, 2018 Synlogic Joins Russell 3000® Index June 11, 2018 Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria June 4, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week® May 15, 2018 Synlogic Reports First Quarter 2018 Financial Results and Provides Business Update May 10, 2018 Synlogic Announces Leadership Change April 25, 2018 Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria April 18, 2018 Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria April 16, 2018 Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting April 6, 2018 Synlogic Announces Registered Direct Offering of Common Stock Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 Next page next › Last page last » Displaying 31 - 40 of 83
June 25, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Immuno-Oncology Program at FOCIS 2018
June 11, 2018 Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria
June 4, 2018 Synlogic Presents New Preclinical Data from Synthetic Biotic™ Medicine, SYNB1020, Highlighting Beneficial Activity in Animal Model of Liver Disease at Digestive Disease Week®
April 25, 2018 Synlogic Receives Fast-Track Designation for SYNB1618, a Synthetic Biotic™ medicine for the Treatment of Phenylketonuria
April 18, 2018 Synlogic Doses First Subject in Phase 1/2a Trial of SYNB1618 for Treatment of Phenylketonuria
April 16, 2018 Synlogic Presents Preclinical Data from Synthetic Biotic Immuno-Oncology Program at the American Association for Cancer Research 2018 Annual Meeting